Consumer Defensive
Live Price
Offline$0.654
+1.87% today
1Y Change
-59.38%
Window
Jun 20, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
The Beauty Health Company (SKIN) is a Consumer Defensive stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $0.65 and down 59.4% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -10.0%, EPS growth of +65.2%, a dividend yield of 0.0%. What stands out right now is revenue -10.0%, EPS +65.2%, free cash flow +298.1% with operating margin -6.9% and ROIC -4.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SKIN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SKIN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SKIN Max Drawdown
-77.95%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SKIN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$260.1M
-28.9% YoY
FY Net Income
-$378.8M
-956.5% YoY
Free Cash Flow
-$44.0M
+64.5% YoY
Revenue Growth
-10.0%
EPS Growth
+65.2%
Gross Margin
65.3%
Net Margin
-3.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 301M | 334M | 398M | 366M | 260M |
| Gross Profit | 196M | 182M | 155M | 249M | 179M |
| Operating Income | -21M | -68M | -131M | -26M | -40M |
| EBITDA | 33K | 10M | -54M | 82M | -351M |
| Net Income | -10M | -29M | -100M | 44M | -379M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 233M | 370M | 523M | 568M | 902M |
| Total Assets | 500M | 686M | 929M | 1.0B | 1.2B |
| Total Liabilities | 439M | 634M | 870M | 836M | 917M |
| Shareholder Equity | 61M | 52M | 59M | 167M | 302M |
| Total Debt | 379M | 568M | 752M | 752M | 746M |
| Net Debt | 146M | 198M | 229M | 184M | -155M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
28M
+73.4% YoY
Capital Expenditures
16M
+10.2% YoY
Free Cash Flow
44M
+64.5% YoY
Key ratios
Gross Margin
65.3%
Operating Margin
-6.9%
Net Margin
-3.2%
ROE
-15.4%
Debt / Equity
6.20x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.